drugset / Trial / NCT04197492

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

NCT04197492 ↗

Phase 2 Unknown 22 enrolled Huashan Hospital
NaSingle-groupOpen-labelTreatment

Summary

A Phase II Study of Hypofractionated Stereotactic Radiotherapy (HSRT) With Anlotinib in Patients With Recurrent High-Grade Glioma. The primary endpoint is overall survival after radiotherapy. Secondary endpoints included progress-free survival, objective response rate, cognitive function, quality of life, toxicity.

Timeline

Start
2019-12-16
Primary completion
2023-12-31
Completion
2024-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg Oral

Indications